Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):477–481. doi: 10.1038/bjc.1996.84

Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression.

H W van den Berg 1, D Claffie 1, M Boylan 1, J McKillen 1, M Lynch 1, B McKibben 1
PMCID: PMC2074471  PMID: 8595162

Abstract

We have investigated the expression of insulin-like growth factor I receptors (IGFR) by the ZR-75-1 human breast cancer cell line and tamoxifen-resistant (ZR-75-9a1) and oestrogen-independent (ZR-PR-LT) variants. ZR-75-1 cells expressed 6633+/-953 receptors per cell,(K(d) 0.24+/-0.06 nM). IGFR expression was reduced in ZR-75-9a1 cells (1180+/-614 receptors per cell, K(d) 0.13+/-0.05) and increased in the ZR-PR-LT cell line (18 430+/-3210 receptors per cell, K(d) 0.24+/-17). A comparison of these data with previously published findings for epidermal growth factor receptor (EGFR) expression by these cell lines revealed that IGFR and EGFR expression are inversely related in the variant lines whereas ZR-75-1 cells express similar numbers of both receptors. Since the changes in IGFR expression observed are associated with changes in steroid hormone receptor status, we also investigated the effects of oestradiol, the synthetic progestin ORG 2058 and dexamethasone on IGFR expression. Oestradiol increased IGFR expression only in the ZR-75-1 cell line. Low concentrations of ORG 2058 increased IGFR levels in the two cell lines positive for progesterone receptor (ZR-75-1 and ZR-PR-LT). High concentrations of ORG 2058 increased IGFR expression in all cell lines, as did dexamethasone. These data suggest that EGFR and IGFR expression may be linked in breast cancer, and that EGFR/IGFR ratios in breast cancer may be a more sensitive prognostic indicator than EGFR expression alone. Regardless of basal IGFR expression by the cell studied, ORG 2058 increased IGFR expression, possibly via both the progesterone and glucocorticoid receptors.

Full text

PDF
477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreatta-Van Leyen S., Hembree J. R., Eckert R. L. Regulation of insulin-like growth factor 1 binding protein 3 levels by epidermal growth factor and retinoic acid in cervical epithelial cells. J Cell Physiol. 1994 Aug;160(2):265–274. doi: 10.1002/jcp.1041600208. [DOI] [PubMed] [Google Scholar]
  2. Ewing T. M., Murphy L. J., Ng M. L., Pang G. Y., Lee C. S., Watts C. K., Sutherland R. L. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer. 1989 Oct 15;44(4):744–752. doi: 10.1002/ijc.2910440432. [DOI] [PubMed] [Google Scholar]
  3. Foekens J. A., Portengen H., van Putten W. L., Trapman A. M., Reubi J. C., Alexieva-Figusch J., Klijn J. G. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):7002–7009. [PubMed] [Google Scholar]
  4. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  5. Hana V., Murphy L. J. Interdependence of epidermal growth factor and insulin-like growth factor-I expression in the mouse uterus. Endocrinology. 1994 Jul;135(1):107–112. doi: 10.1210/endo.135.1.8013342. [DOI] [PubMed] [Google Scholar]
  6. Harris A. L., Nicholson S., Sainsbury J. R., Farndon J., Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem. 1989;34(1-6):123–131. doi: 10.1016/0022-4731(89)90072-1. [DOI] [PubMed] [Google Scholar]
  7. Hembree J. R., Agarwal C., Eckert R. L. Epidermal growth factor suppresses insulin-like growth factor binding protein 3 levels in human papillomavirus type 16-immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor 1. Cancer Res. 1994 Jun 15;54(12):3160–3166. [PubMed] [Google Scholar]
  8. Keightley D. D., Cressie N. A. The Woolf plot is more reliable than the Scatchard plot in analysing data from hormone receptor assays. J Steroid Biochem. 1980 Nov;13(11):1317–1323. doi: 10.1016/0022-4731(80)90092-8. [DOI] [PubMed] [Google Scholar]
  9. Lahti E. I., Knip M., Laatikainen T. J. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer. 1994 Jul 15;74(2):618–624. doi: 10.1002/1097-0142(19940715)74:2<618::aid-cncr2820740213>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  10. Long B., McKibben B. M., Lynch M., van den Berg H. W. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer. 1992 Jun;65(6):865–869. doi: 10.1038/bjc.1992.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lønning P. E., Hall K., Aakvaag A., Lien E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992 Sep 1;52(17):4719–4723. [PubMed] [Google Scholar]
  12. Manni A., Badger B., Wei L., Zaenglein A., Grove R., Khin S., Heitjan D., Shimasaki S., Ling N. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res. 1994 Jun 1;54(11):2934–2942. [PubMed] [Google Scholar]
  13. Nicholson S., Sainsbury J. R., Needham G. K., Chambers P., Farndon J. R., Harris A. L. Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer. 1988 Jul 15;42(1):36–41. doi: 10.1002/ijc.2910420108. [DOI] [PubMed] [Google Scholar]
  14. Osborne C. K., Coronado E. B., Kitten L. J., Arteaga C. I., Fuqua S. A., Ramasharma K., Marshall M., Li C. H. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov;3(11):1701–1709. doi: 10.1210/mend-3-11-1701. [DOI] [PubMed] [Google Scholar]
  15. Owens P. C., Gill P. G., De Young N. J., Weger M. A., Knowles S. E., Moyse K. J. Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells. Biochem Biophys Res Commun. 1993 Jun 15;193(2):467–473. doi: 10.1006/bbrc.1993.1647. [DOI] [PubMed] [Google Scholar]
  16. Papa V., Hartmann K. K., Rosenthal S. M., Maddux B. A., Siiteri P. K., Goldfine I. D. Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II. Mol Endocrinol. 1991 May;5(5):709–717. doi: 10.1210/mend-5-5-709. [DOI] [PubMed] [Google Scholar]
  17. Pekonen F., Partanen S., Mäkinen T., Rutanen E. M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988 Mar 1;48(5):1343–1347. [PubMed] [Google Scholar]
  18. Pollak M. N., Huynh H. T., Lefebvre S. P. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat. 1992;22(1):91–100. doi: 10.1007/BF01833337. [DOI] [PubMed] [Google Scholar]
  19. Railo M. J., von Smitten K., Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994;30A(3):307–311. doi: 10.1016/0959-8049(94)90247-x. [DOI] [PubMed] [Google Scholar]
  20. Schäffer L., Larsen U. D., Linde S., Hejnaes K. R., Skriver L. Characterization of the three 125I-iodination isomers of human insulin-like growth factor I (IGF1). Biochim Biophys Acta. 1993 Dec 8;1203(2):205–209. doi: 10.1016/0167-4838(93)90084-5. [DOI] [PubMed] [Google Scholar]
  21. Stewart A. J., Johnson M. D., May F. E., Westley B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990 Dec 5;265(34):21172–21178. [PubMed] [Google Scholar]
  22. van den Berg H. W., Lynch M., Martin J. H. The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor. Eur J Cancer. 1993;29A(12):1771–1775. doi: 10.1016/0959-8049(93)90122-v. [DOI] [PubMed] [Google Scholar]
  23. van den Berg H. W., Lynch M., Martin J., Nelson J., Dickson G. R., Crockard A. D. Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br J Cancer. 1989 Apr;59(4):522–526. doi: 10.1038/bjc.1989.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van den Berg H. W., Martin J., Lynch M. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions. Br J Cancer. 1990 Apr;61(4):504–507. doi: 10.1038/bjc.1990.114. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES